We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

121 hedge funds and large institutions have $383M invested in Progenics Pharmaceuticals Inc in 2015 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 39 increasing their positions, 44 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more call options, than puts

Call options by funds: $1.02M | Put options by funds: $706K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1% less capital invested

Capital invested by funds: $385M → $383M (-$2.68M)

9% less funds holding

Funds holding: 133121 (-12)

11% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 44

50% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 24

Holders
121
Holders Change
-12
Holders Change %
-9.02%
% of All Funds
3.17%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
12
Increased
39
Reduced
44
Closed
24
Calls
$1.02M
Puts
$706K
Net Calls
+$310K
Net Calls Change
+$56K
Name Holding Trade Value Shares
Change
Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$82.8M
BC
2
Broadfin Capital
New York
$54.9M
Fidelity Investments
3
Fidelity Investments
Massachusetts
$32.1M -$589K -89,872 -2%
BBA
4
Baker Bros. Advisors
New York
$26.7M
BFA
5
BlackRock Fund Advisors
California
$16.6M -$887K -135,302 -5%
Vanguard Group
6
Vanguard Group
Pennsylvania
$14.6M +$224K +34,224 +1%
Tudor Investment Corp
7
Tudor Investment Corp
Connecticut
$14.5M -$140K -21,339 -0.9%
State Street
8
State Street
Massachusetts
$14.4M -$14.1M -2,151,246 -48%
RA
9
Royce & Associates
New York
$14M -$4.57M -696,700 -23%
Millennium Management
10
Millennium Management
New York
$13.9M -$63.6K -9,698 -0.4%
BIT
11
BlackRock Institutional Trust
California
$11M -$244K -37,167 -2%
NI
12
Numeric Investors
Massachusetts
$5.5M +$1.9M +290,299 +48%
RHJA
13
Rice Hall James & Associates
California
$5.47M +$2.69M +409,618 +85%
Northern Trust
14
Northern Trust
Illinois
$4.83M +$75.3K +11,492 +1%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$3.96M -$79.4K -12,117 -2%
PFC
16
Phocas Financial Corp
California
$3.9M +$298K +45,414 +8%
KCM
17
Kennedy Capital Management
Missouri
$3.81M -$13.3K -2,024 -0.3%
Fuller & Thaler Asset Management
18
Fuller & Thaler Asset Management
California
$3.73M +$191K +29,200 +5%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$3.4M -$549K -83,800 -13%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$3.17M -$12.8K -1,947 -0.4%
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$2.69M +$774K +117,995 +37%
GCP
22
GSA Capital Partners
United Kingdom
$2.67M -$283K -43,101 -9%
TC
23
TFS Capital
Pennsylvania
$2.44M +$2.19M +334,774 +527%
Wellington Management Group
24
Wellington Management Group
Massachusetts
$2.44M -$2.97M -453,321 -53%
PCM
25
Piermont Capital Management
Missouri
$2.23M

PGNX Hedge Fund Activity: Q4 2015 in Review

121 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2015, worth a combined $383M — down 0.7% from $385M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of PGNX and 12 opened new positions — a net loss of 12 holders — while 44 trimmed existing stakes and 39 added.

The largest buyer was Rice Hall James & Associates, adding an estimated $2.69M. The largest seller was State Street, cutting an estimated $14.1M.

  • 121 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2015, down from 133 in Q3 2015.
  • Funds reported $383M of Progenics Pharmaceuticals Inc stock for Q4 2015, down 0.7% quarter-over-quarter.
  • 12 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2015 and 24 closed out, a net change of -12 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q4 2015 was Rice Hall James & Associates, an estimated $2.69M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q4 2015 was State Street, an estimated $14.1M sold.

Based on aggregated 13F filings for Q4 2015.